Shanghai 's Asieris Pharma and Beijing 's BeiGene plan to test a combination of Asieris' MetAP2 inhibitor and BeiGene's PD-L1 inhibitor in bladder cancer patients. Asieris' APL-1202 is an oral drug that has anti-angiogenic, anti-tumor effects and also modulates the tumor immune microenvironment. BeiGene's tislelizumab binds PD-1 to restore an immune response for cancer. The Phase I/II trial will test the safety and efficacy of the combination in patients with muscle invasive bladder cancer (MIBC). Asieris plans to submit INDs in  China  and the US . More details.... Stock Symbol: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //